Last reviewed · How we verify
NCT03501121: TARGIT-X
Extended Follow up of the TARGIT-A Trial
trial in Breast Neoplasm Female in 714 participants. Status unknown.
31 January 2023
Quick facts
| Lead sponsor | University College, London |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 714 |
| Start date | 16 August 2018 |
| Primary completion | 31 January 2023 |
| Estimated completion | 31 January 2023 |
| Sites | 2 locations across United Kingdom |
Conditions studied
- Breast Neoplasm Female — all drugs for Breast Neoplasm Female →
Sponsor
University College, London
Who can join
45 and older, female only, with Breast Neoplasm Female. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
All UK patients who participated in the TARGIT-A Trial were initially treated for early breast cancer between 2000-2012. A total of 3451 patients from 33 hospitals in 11 countries participated in the trial and a comparison was made between traditional radiotherapy given over several weeks (external beam radiotherapy, EBRT) with TARGeted Intraoperative radioTherapy (TARGIT-IORT) as a single dose given during the operation to remove the breast cancer. The trial was funded by the Health Technology Assessment (HTA) programme of the Department of Health, UK and sponsored by University College London. The results from this trial have been published in major medical journals and have already started changing the way breast cancer in treated around the world; please see www.targit.org.uk for more details. We would like to continue to collect data about the health status of all patients to enable us to learn about longer term differences in the effects of these treatments on health. An analysis of this information could improve treatment for patients with breast cancer. For this, HTA have granted us further funding.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A novel methodology using direct patient contact and UK national registries to collect long-term data from randomised trials: TARGIT-X - an extended follow-up study of the TARGIT-A trial of targeted intraoperative radiotherapy for breast cancer.
Vaidya JS, Williams NR, Bulsara M, Brew-Graves C, et al · · 2026 · PMID 42011087 · DOI 10.3310/gjjv2820
Verify or expand the search:
- PubMed search for NCT03501121
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Neoplasm Female
Currently open trials in the same condition.
- NCT07465523 — A Novel Approach in the Evaluation of Breast Masses With Doppler US · recruiting
- NCT06711523 — Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy · Phase 3 · active not recruiting
- NCT05277935 — Wearable Enhanced Fitness Tracking for Metastatic Breast Cancer Patients Using Endocrine Treatment and Palbociclib · NA · recruiting
- NCT06234137 — A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrot · NA · recruiting
- NCT04812652 — Digitally Distributed Yoga for Women Treated for Breast Cancer · NA · active not recruiting
Other University College, London trials
Trials by the same sponsor.
- NCT07386652 — Intensive Comprehensive Aphasia Programme for People With Post-Stroke Aphasia · NA · not yet recruiting
- NCT06924086 — The Children's Adaptive Deep Brain Stimulation for Epilepsy Trial · NA · recruiting
- NCT07386678 — Study of Imaging and Molecular Biomarkers in Uncomplicated Rhegmatogenous Retinal Detachment · not yet recruiting
- NCT07414940 — ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium · Phase 1, PHASE2 · not yet recruiting
- NCT07214454 — TCDS for the Treatment of Chronic Migraine · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03501121 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University College, London
- Last refreshed: 6 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03501121.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing